TARA Protara Therapeutics, Inc. - Common Stock
$4,08
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 11, 2026
52W-Spanne
$3–$8
23% of range
Analystenbewertung
BUY
14 analysts
Kursziel
$27
+552% upside
P/E (TTM)
-3.0
ROE
-33.7%
Nettogewinnmarge
—
Über Protara Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
Mehr lesen
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
Company History
Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.
The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.
On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. The company went public in 2014.
In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.
PRT-201
Proteon is developing PRT-201 (vonapanitase), a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). PRT-201 is a recombinant human elastase manufactured for Proteon by Lonza.
In September 2008, the company announced that the Food and Drug Administration had granted fast track status to PRT-201.
In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
TARA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.08
Marktkapitalisierung
$218M
P/E (TTM)
-3.0
EPS (TTM)
$-1.34
Umsatz (TTM)
—
Dividendenrendite
—
ROE
-33.7%
Verschuldungsgrad
—
52W-Spanne
$3 – $8
TARA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
—
EPS
$-1.34
2021-12-31
→
2025-12-31
Freier Cashflow
$-56M
2016-12-31
→
2025-12-31
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
TARA
Peer-Median
P/E (TTM)
-3.0
88.5
P/B (K/B)
1.1
3.6
Price / FCF (Kurs / FCF)
-3.9
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
TARA
Peer-Median
ROA
-29.4%
-38.8%
ROE
-33.7%
-61.0%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
TARA
Peer-Median
Current Ratio (Liquiditätsgrad)
14.6
3.9
Quick Ratio
14.2
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
TARA
Peer-Median
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
TARA
Peer-Median
TARA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
14 Analysten
- Starker Kauf 3 21,4%
- Kauf 10 71,4%
- Halten 1 7,1%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
7 Analysten · 2026-08-13
Median
$26.00
Mittelwert
$26.57
← Unter allen Zielen
$4.08
Tief
$24.00
Hoch
$30.00
Median-Ziel
$26.00
+538,0%
Mittelwert-Ziel
$26.57
+552,1%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.07%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. März 2026 | $-0.31 | $-0.38 | 0.07% |
| 31. Dezember 2025 | $-0.37 | $-0.33 | -0.04% |
| 30. September 2025 | $-0.31 | $-0.39 | 0.08% |
| 30. Juni 2025 | $-0.35 | $-0.41 | 0.06% |
| 31. März 2025 | $-0.29 | $-0.46 | 0.17% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| GLSI | $300M | -14.7 | — | — | -2159.7% | — |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | — |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | — |
| NERV | $174M | -0.1 | — | — | 339.5% | — |
| RNA | $10.91B | -14.5 | 72.1% | -3650.4% | -47.5% | — |
| CNXU | — | — | — | — | — | — |
| IMUX | — | -0.9 | — | — | — | — |
| TNXP | $200M | -1.1 | 29.8% | -946.2% | -60.0% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| R&D Expense | $43M | $32M | $25M | $17M | $21M | $12M | $4M | $12M | $22M | $19M | $12M | $6M | |
| SG&A Expense | $22M | $17M | $19M | $21M | $26M | $22M | $4M | $10M | $9M | $10M | $8M | $4M | |
| Operating Expenses | $65M | $49M | $44M | $67M | $47M | $34M | $8M | $21M | $30M | $29M | $21M | $11M | |
| Operating Income | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-8M | |
| Interest Expense | · | · | · | · | $0 | $34.0K | · | · | · | · | · | $857.0K | |
| Interest Income | $6M | $4M | $3M | $1M | $237.0K | $500.0K | · | · | · | · | · | · | |
| Other Non-op | $7M | $5M | $3M | $1M | $237.0K | $466.0K | · | $207.0K | $139.0K | $-14.0K | $-651.0K | $5M | |
| Pretax Income | $57M | $45M | · | · | · | · | $-15M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $-110.0K | |
| Net Income | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| EPS (Basic) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| Shares (Basic) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | · | · | · | · | · | · | · | · | |
| Shares (Diluted) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | 11,232,576 | · | · | · | · | · | · | · | |
| EBITDA | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-15M | · | · | $-29M | $-21M | $-8M |
Bilanz 23
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50M | $163M | $40M | $24M | $36M | $169M | $564.0K | $19M | $21M | $36M | $40M | $69M | |
| Short-term Investments | $106M | $7M | $26M | $60M | $56M | · | · | $2M | $21M | $5M | $25M | $15M | |
| Prepaid Expense | $4M | $2M | $3M | $2M | $2M | $787.0K | $78.0K | $1M | $1M | $1M | $1M | $1M | |
| Other Current Assets | $65.0K | $2.0K | $37.0K | $127.0K | $34.0K | $52.0K | · | · | · | · | · | · | |
| Current Assets | $160M | $172M | $69M | $86M | $93M | $169M | $764.0K | $23M | $43M | $43M | $67M | $85M | |
| PP&E (Net) | $759.0K | $1M | $1M | $2M | $2M | $1M | $459.0K | $263.0K | $259.0K | $372.0K | $224.0K | $83.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $1M | $475.0K | $1M | $971.0K | $937.0K | $665.0K | $467.0K | |
| Accum. Depreciation | $1M | $1M | $824.0K | $483.0K | $236.0K | $119.0K | $16.0K | $827.0K | $712.0K | $565.0K | $441.0K | $384.0K | |
| Goodwill | · | · | · | · | $30M | $30M | · | · | · | · | · | · | |
| Other Non-current Assets | $20.0K | $27.0K | $11.0K | $16.0K | $865.0K | $1M | · | · | $218.0K | $393.0K | $706.0K | $114.0K | |
| Total Assets | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Accounts Payable | $3M | $4M | $2M | $2M | $954.0K | $914.0K | $716.0K | $441.0K | $291.0K | $556.0K | $1M | $917.0K | |
| Accrued Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $3M | $3M | $9M | $5M | $3M | $1M | |
| Current Liabilities | $11M | $11M | $6M | $6M | $4M | $3M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Capital Leases | $2M | $3M | $4M | $5M | $6M | $999.0K | · | · | · | · | · | · | |
| Total Liabilities | $13M | $14M | $11M | $11M | $11M | $4M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Common Stock | $54.0K | $35.0K | $11.0K | $11.0K | $11.0K | $11.0K | $3.0K | · | $18.0K | $17.0K | $16.0K | $16.0K | |
| Paid-in Capital | $499M | $412M | $269M | $263M | $256M | $246M | $11M | $209M | $203M | $198M | $195M | $192M | |
| Retained Earnings | $-302M | $-245M | $-200M | $-160M | $-94M | $-47M | $-13M | $-210M | $-190M | $-160M | $-131M | $-110M | |
| AOCI | $90.0K | $2.0K | $-31.0K | $-688.0K | $-211.0K | · | $3.0K | $5.0K | $-14.0K | · | $-11.0K | $-6.0K | |
| Stockholders' Equity | $196M | $167M | $68M | $102M | $162M | $199M | $-2M | $5M | $35M | $38M | $63M | $82M | |
| Liabilities + Equity | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Shares Outstanding | 53,587,260 | 35,044,772 | 11,364,903 | 11,267,389 | 11,235,731 | 11,211,840 | 2,627,533 | 481,091 | 17,674,729 | 16,603,559 | 16,501,500 | 16,448,455 |
Cashflow 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $123.0K | $57.0K | $30.0K | |
| Stock-based Comp | $4M | $4M | $6M | $7M | $10M | $10M | $424.0K | $3M | $3M | $3M | $2M | $459.0K | |
| Deferred Tax | $-11M | $-20M | $-14M | $-9M | $-5M | $-9M | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | $3M | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $1M | $2M | $-7M | |
| Operating Cash Flow | $-56M | $-36M | $-38M | $-26M | $-35M | $-23M | $-5M | $-23M | $-22M | $-24M | $-18M | $-10M | |
| CapEx | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K | $198.0K | $51.0K | |
| Investing Cash Flow | $-139M | $19M | $53M | $15M | $-98M | $3M | $-475.0K | $18M | $-16M | $20M | $-11M | · | |
| Stock Issued | · | · | · | · | · | $74M | · | · | · | · | · | $62M | |
| Stock Repurchased | · | · | $91.0K | $90.0K | $228.0K | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | $-91.0K | $-90.0K | $-228.0K | $66M | · | · | · | · | · | $62M | |
| Financing Cash Flow | $83M | $140M | $-91.0K | $-90.0K | $-228.0K | $189M | $500.0K | $3M | $23M | $208.0K | $163.0K | · | |
| Net Change in Cash | · | · | · | · | · | · | $-13M | $-2M | $-15M | $-4M | $-29M | $66M | |
| Free Cash Flow | $-56M | $-36M | $-38M | $-27M | $-35M | $-24M | $-16M | · | · | $-24M | $-18M | $-10M |
Rentabilität 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -257.1% | |
| Net Margin | · | · | · | · | · | -7291.4% | · | · | · | · | · | -113.4% | |
| EBITDA Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -256.1% | |
| ROA | -29.4% | -34.2% | -42.0% | -46.1% | -25.1% | -33.2% | -98.3% | · | · | -51.4% | -28.1% | -7.4% | |
| ROE | -33.7% | -35.8% | -55.6% | -54.7% | -28.4% | -17.2% | -449.1% | · | · | -56.0% | -29.3% | 37.0% |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 | 58.1 | 12.0 | · | · | 8.4 | 16.1 | 36.2 | |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 | 57.8 | 10.6 | · | · | 8.1 | 15.8 | 35.8 | |
| Interest Coverage | · | · | · | · | · | -1013.1 | · | · | · | · | · | -8.8 |
Effizienz 1
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | 0.1 |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Net Income TTM | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Market Cap | $286M | $185M | $21M | $30M | $76M | $271M | $9M | · | · | $1.26B | $10.24B | $6.84B | |
| P/E | -4.0 | -2.4 | -0.5 | -0.5 | -1.6 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 2321.1 | |
| P/B | 1.5 | 1.1 | 0.3 | 0.3 | 0.5 | 1.4 | 1.4 | · | · | 32.8 | 161.5 | 83.0 | |
| P / Tangible Book | 1.5 | 1.1 | 0.3 | 0.3 | 0.6 | 1.6 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.6 | -0.6 | · | · | -53.3 | -582.8 | -684.9 | |
| P / FCF | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.2 | -0.6 | · | · | -52.7 | -576.3 | -681.5 | |
| Earnings Yield | -25.1% | -41.1% | -190.4% | -218.7% | -62.4% | · | · | · | · | · | · | · |
Gewinn- und Verlustrechnung 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $17M | $14M | $13M | $10M | $11M | $9M | $9M | $8M | $6M | $8M | $6M | $6M | $7M | $5M | $5M | $3M | |
| SG&A Expense | $6M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | $4M | $5M | $4M | $5M | $5M | $5M | $5M | |
| Operating Expenses | $23M | $20M | $19M | $15M | $17M | $14M | $14M | $12M | $11M | $12M | $11M | $11M | $12M | $10M | $40M | $8M | |
| Operating Income | $-23M | $-20M | $-19M | $-15M | $-17M | $-14M | $-14M | $-12M | $-11M | $-12M | $-11M | $-11M | $-12M | $-10M | $-40M | $-8M | |
| Interest Income | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Other Non-op | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Net Income | $-22M | $-18M | $-17M | $-13M | $-15M | $-12M | $-13M | $-11M | $-10M | $-11M | $-10M | $-10M | $-11M | $-9M | $-39M | $-8M | |
| EPS (Basic) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| EPS (Diluted) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| Shares (Basic) | 61,006,766 | 57,538,833 | -82,414,767 | 42,272,104 | 42,270,855 | 40,707,937 | -34,391,036 | 22,329,772 | 21,233,163 | 11,420,948 | -22,628,260 | 11,347,887 | 11,307,842 | 11,303,869 | -22,511,202 | 11,265,475 | |
| Shares (Diluted) | 61,006,766 | 57,538,833 | -82,414,767 | 42,272,104 | 42,270,855 | 40,707,937 | -34,391,036 | 22,329,772 | 21,233,163 | 11,420,948 | -22,628,260 | 11,347,887 | 11,307,842 | 11,303,869 | -22,511,202 | 11,265,475 | |
| EBITDA | $-23M | $-20M | · | $-15M | $-17M | $-14M | · | $-12M | $-11M | $-12M | · | $-11M | $-12M | $-10M | · | $-8M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $15M | $50M | $13M | $31M | $91M | $163M | $52M | $90M | $52M | $40M | $34M | $34M | $21M | $24M | $47M | |
| Short-term Investments | $125M | $121M | $106M | $120M | $91M | $33M | $7M | $30M | · | $3M | $26M | $40M | $46M | $66M | $60M | $49M | |
| Prepaid Expense | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $4M | $3M | $3M | $3M | $4M | $4M | $8M | $2M | $2M | |
| Other Current Assets | $230.0K | $17.0K | $65.0K | $218.0K | $78.0K | $16.0K | $2.0K | $3.0K | $4.0K | $3.0K | $37.0K | $2.0K | $1.0K | $127.0K | $127.0K | · | |
| Current Assets | $146M | $140M | $160M | $136M | $125M | $127M | $172M | $85M | $92M | $58M | $69M | $78M | $84M | $95M | $86M | $99M | |
| PP&E (Net) | $1M | $669.0K | $759.0K | $828.0K | $912.0K | $988.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | $824.0K | · | · | · | $483.0K | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Assets | $74.0K | $76.0K | $20.0K | $21.0K | $29.0K | $35.0K | $27.0K | $33.0K | $19.0K | $31.0K | $11.0K | $3M | $3M | $586.0K | $16.0K | $734.0K | |
| Total Assets | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Accounts Payable | $5M | $4M | $3M | $5M | $5M | $2M | $4M | $2M | $1M | $972.0K | $2M | $3M | $2M | $4M | $2M | $456.0K | |
| Accrued Liabilities | $7M | $4M | $6M | $4M | $3M | $4M | $5M | $5M | $3M | $4M | $3M | $3M | $2M | $1M | $3M | $2M | |
| Current Liabilities | $13M | $9M | $11M | $10M | $10M | $7M | $11M | $9M | $6M | $6M | $6M | $7M | $5M | $6M | $6M | $4M | |
| Capital Leases | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | |
| Total Liabilities | $15M | $11M | $13M | $12M | $13M | $10M | $14M | $12M | $10M | $10M | $11M | $12M | $10M | $12M | $11M | $9M | |
| Common Stock | $59.0K | $55.0K | $54.0K | $39.0K | $39.0K | $39.0K | $35.0K | $21.0K | $21.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | |
| Paid-in Capital | $503M | $502M | $499M | $417M | $416M | $415M | $412M | $314M | $313M | $270M | $269M | $267M | $266M | $264M | $263M | $261M | |
| Retained Earnings | $-342M | $-320M | $-302M | $-285M | $-272M | $-257M | $-245M | $-232M | $-221M | $-211M | $-200M | $-190M | $-180M | $-169M | $-160M | $-121M | |
| AOCI | $-363.0K | $-364.0K | $90.0K | $143.0K | $77.0K | $89.0K | $2.0K | $29.0K | · | $-1.0K | $-31.0K | $-165.0K | $-336.0K | $-469.0K | $-688.0K | $-1M | |
| Stockholders' Equity | $161M | $181M | $196M | $132M | $144M | $158M | $167M | $82M | $92M | $58M | $68M | $77M | $85M | $95M | $102M | $139M | |
| Liabilities + Equity | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Shares Outstanding | 59,083,935 | 55,055,582 | 53,587,260 | 38,587,260 | 38,581,863 | 38,577,813 | 35,044,772 | 20,629,772 | 11,364,903 | 11,433,837 | 11,364,903 | 11,364,903 | 11,307,962 | 11,306,753 | 11,267,389 | 11,267,389 |
Cashflow 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $903.0K | $833.0K | $904.0K | $931.0K | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | |
| Operating Cash Flow | $-15M | $-21M | $-17M | $-12M | $-12M | $-15M | $-9M | $-8M | $-8M | $-10M | $-9M | $-7M | $-9M | $-13M | $-5M | $-5M | |
| CapEx | · | · | $24.0K | $4.0K | $22.0K | $44.0K | $0 | $8.0K | · | · | $0 | $37.0K | $2.0K | $6.0K | $6.0K | $83.0K | |
| Investing Cash Flow | $18M | $-15M | $-27M | $-7M | $-48M | $-58M | $22M | $-29M | $3M | $23M | $15M | $6M | $22M | $10M | $-18M | $19M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | $76.0K | · | $27.0K | $0 | $64.0K | $0 | $18.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $-76.0K | · | · | · | $-64.0K | · | · | |
| Financing Cash Flow | $-26.0K | $1M | $81M | $13.0K | $8.0K | $2M | $98M | $0 | $42M | $-76.0K | $0 | $-27.0K | $0 | $-64.0K | $0 | $-18.0K | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | · | · | · | · | $-13M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -1464.0% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -13.0% | -9.9% | · | -11.1% | -11.6% | -10.1% | · | -12.3% | -9.7% | -12.7% | · | -8.3% | -9.0% | -6.8% | · | -4.7% | |
| ROE | -14.2% | -10.5% | · | -12.4% | -12.7% | -11.0% | · | -14.1% | -10.7% | -14.5% | · | -9.1% | -9.8% | -7.3% | · | -5.0% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 15.7 | · | 13.7 | 12.8 | 18.0 | · | 9.8 | 16.3 | 10.5 | · | 11.5 | 17.1 | 14.8 | · | 26.6 | |
| Quick Ratio | 10.7 | 15.2 | · | 13.4 | 12.5 | 17.7 | · | 9.4 | 15.9 | 10.0 | · | 10.9 | 16.3 | 13.5 | · | 26.0 |
Effizienz 1
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-68M | $-58M | · | $-51M | $-48M | $-44M | · | $-42M | $-42M | $-41M | · | $-38M | $-37M | $-36M | · | $-38M | |
| Market Cap | $226M | $287M | · | $168M | $117M | $164M | · | $38M | $24M | $46M | · | $19M | $27M | $35M | · | $33M | |
| P/E | -2.9 | -4.1 | · | -3.0 | -1.9 | -1.9 | · | -0.7 | -0.6 | -1.1 | · | -0.5 | -0.7 | -1.0 | · | -0.9 | |
| P/B | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.2 | |
| P / Tangible Book | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -11.2 | · | · | · | -4.4 | · | · | · | -2.7 | · | · | |
| P / FCF | · | · | · | · | · | -11.1 | · | · | · | · | · | · | · | -2.7 | · | · | |
| Earnings Yield | -34.8% | -24.2% | · | -33.3% | -52.5% | -51.9% | · | -152.5% | -158.2% | -90.8% | · | -200.6% | -135.6% | -102.2% | · | -113.5% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Nettoergebnis | $-57M | $-45M | $-40M | $-66M | $-47M |
| Verwässerte EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-56M | $-36M | $-38M | $-27M | $-35M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 127 Einreicher · $162.3M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 31 (+4 vs. Vorquartal) | 16 (-5 vs. Vorquartal) | 39 (-8 vs. Vorquartal) | 33 (+10 vs. Vorquartal) | +760K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $27.154.562 | 5.207.011 | 16,73% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $11.846.454 | 3.101.166 | 7,30% | Aktien |
| Velan Capital Investment Management LP | $10.866.571 | 2.844.652 | 6,70% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.786.508 | 2.300.133 | 5,41% | Aktien |
| Blackstone Inc. | $8.654.263 | 2.265.514 | 5,33% | Aktien |
| ORBIMED ADVISORS LLC | $8.480.400 | 2.220.000 | 5,23% | Aktien |
| Sio Capital Management, LLC | $7.341.551 | 1.921.872 | 4,52% | Aktien |
| ACORN CAPITAL ADVISORS, LLC | $6.693.079 | 1.752.115 | 4,12% | Aktien |
| Integral Health Asset Management, LLC | $5.730.000 | 1.500.000 | 3,53% | Aktien |
| 5AM Venture Management, LLC | $5.232.567 | 1.369.782 | 3,22% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $4.362.540 | 1.141.710 | 2,69% | Aktien |
| STATE STREET CORP | $4.080.887 | 1.068.295 | 2,51% | Aktien |
| Qube Research & Technologies Ltd | $3.993.871 | 1.045.516 | 2,46% | Aktien |
| Balyasny Asset Management L.P. | $3.921.960 | 1.026.691 | 2,42% | Aktien |
| BAKER BROS. ADVISORS LP | $3.711.565 | 971.614 | 2,29% | Aktien |
| ADAR1 Capital Management, LLC | $3.592.756 | 940.512 | 2,21% | Aktien |
| CITADEL ADVISORS LLC | $3.414.045 | 893.729 | 2,10% | Aktien |
| BANK OF AMERICA CORP /DE/ | $3.287.679 | 860.649 | 2,03% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $2.389.918 | 625.633 | 1,47% | Aktien |
| Point72 Asset Management, L.P. | $2.096.920 | 548.932 | 1,29% | Aktien |
| Catalio Capital Management, LP | $1.986.965 | 520.148 | 1,22% | Aktien |
| GOLDMAN SACHS GROUP INC | $1.936.106 | 506.834 | 1,19% | Aktien |
| Walleye Capital LLC | $1.930.750 | 505.432 | 1,19% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.878.130 | 491.657 | 1,16% | Aktien |
| MORGAN STANLEY | $1.833.917 | 480.083 | 1,13% | Aktien |
| UBS Group AG | $1.723.538 | 451.188 | 1,06% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.278.489 | 334.683 | 0,79% | Aktien |
| Verdad Advisers, LP | $1.192.791 | 312.249 | 0,73% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1.129.058 | 295.565 | 0,70% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $960.730 | 251.500 | 0,59% | Aktien |
| OPPENHEIMER & CO INC | $910.543 | 238.362 | 0,56% | Aktien |
| Jump Financial, LLC | $775.842 | 203.100 | 0,48% | Aktien |
| CIBC WORLD MARKET INC. | $636.011 | 166.495 | 0,39% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $603.449 | 157.971 | 0,37% | Aktien |
| J. Goldman & Co LP | $515.700 | 135.000 | 0,32% | Aktien |
| SUPERSTRING CAPITAL MANAGEMENT LP | $463.966 | 121.457 | 0,29% | Aktien |
| Fisher Asset Management, LLC | $380.342 | 99.566 | 0,23% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $376.220 | 98.487 | 0,23% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $325.961 | 85.330 | 0,20% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $266.071 | 69.652 | 0,16% | Aktien |
| FMR LLC | $260.012 | 68.066 | 0,16% | Aktien |
| XTX Topco Ltd | $244.281 | 63.948 | 0,15% | Aktien |
| RHUMBLINE ADVISERS | $241.589 | 63.245 | 0,15% | Aktien |
| TRUIST FINANCIAL CORP | $229.200 | 60.000 | 0,14% | Aktien |
| Assenagon Asset Management S.A. | $229.024 | 59.954 | 0,14% | Aktien |
| Trexquant Investment LP | $227.733 | 59.616 | 0,14% | Aktien |
| DEUTSCHE BANK AG\ | $220.464 | 57.713 | 0,14% | Aktien |
| ALPS ADVISORS INC | $217.897 | 57.041 | 0,13% | Aktien |
| AMERIPRISE FINANCIAL INC | $214.863 | 56.247 | 0,13% | Aktien |
| PRUDENTIAL FINANCIAL INC | $193.789 | 50.730 | 0,12% | Aktien |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $191.000 | 50.000 | 0,12% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $154.252 | 40.380 | 0,10% | Aktien |
| Alyeska Investment Group, L.P. | $151.753 | 39.726 | 0,09% | Aktien |
| Quadrature Capital Ltd | $150.199 | 39.319 | 0,09% | Aktien |
| Marex Group Ltd | $134.655 | 35.250 | 0,08% | Aktien |
| WINTON GROUP Ltd | $125.296 | 32.800 | 0,08% | Aktien |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $113.454 | 29.700 | 0,07% | Aktien |
| MetLife Investment Management, LLC | $108.404 | 28.378 | 0,07% | Aktien |
| MARSHALL WACE, LLP | $106.995 | 28.009 | 0,07% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $93.988 | 18.040 | 0,06% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $92.043 | 24.095 | 0,06% | Aktien |
| WOLVERINE TRADING, LLC | $88.200 | 20.000 | 0,05% | Verkaufsoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $87.478 | 22.900 | 0,05% | Verkaufsoption |
| CITIGROUP INC | $80.698 | 21.125 | 0,05% | Aktien |
| Jain Global LLC | $80.220 | 21.000 | 0,05% | Aktien |
| Invesco Ltd. | $78.295 | 20.496 | 0,05% | Aktien |
| Vanguard Global Advisers, LLC | $76.885 | 20.127 | 0,05% | Aktien |
| PRELUDE CAPITAL MANAGEMENT, LLC | $74.922 | 19.613 | 0,05% | Aktien |
| EntryPoint Capital, LLC | $73.673 | 19.286 | 0,05% | Aktien |
| LPL Financial LLC | $73.077 | 19.130 | 0,05% | Aktien |
| VANGUARD GROUP INC | $70.479 | 13.223 | 0,04% | Aktien |
| Squarepoint Ops LLC | $69.234 | 18.124 | 0,04% | Aktien |
| IEQ CAPITAL, LLC | $68.489 | 17.929 | 0,04% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $67.114 | 17.569 | 0,04% | Aktien |
| BARCLAYS PLC | $60.665 | 15.881 | 0,04% | Aktien |
| BlackRock, Inc. | $58.950 | 15.432 | 0,04% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $56.834 | 14.878 | 0,04% | Aktien |
| INTECH INVESTMENT MANAGEMENT LLC | $51.807 | 13.562 | 0,03% | Aktien |
| WOLVERINE TRADING, LLC | $51.315 | 11.636 | 0,03% | Aktien |
| Mariner, LLC | $45.441 | 11.899 | 0,03% | Aktien |
| Bank of New York Mellon Corp | $43.877 | 11.486 | 0,03% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $43.812 | 11.469 | 0,03% | Aktien |
| D. E. Shaw & Co., Inc. | $42.452 | 11.113 | 0,03% | Aktien |
| COMMONWEALTH EQUITY SERVICES, LLC | $42.020 | 11.000 | 0,03% | Aktien |
| WELLS FARGO & COMPANY/MN | $41.161 | 10.775 | 0,03% | Aktien |
| Essential Partners LLC | $37.444 | 9.802 | 0,02% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $34.525 | 9.038 | 0,02% | Aktien |
| NORTHERN TRUST CORP | $32.061 | 8.393 | 0,02% | Aktien |
| CWM, LLC | $30.458 | 5.846 | 0,02% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $30.178 | 7.900 | 0,02% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $28.788 | 7.536 | 0,02% | Aktien |
| Tower Research Capital LLC (TRC) | $19.062 | 4.990 | 0,01% | Aktien |
| Legal & General Group Plc | $17.129 | 4.490 | 0,01% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $14.645 | 2.811 | 0,01% | Aktien |
| Ameritas Investment Partners, Inc. | $12.598 | 3.298 | 0,01% | Aktien |
| Nuveen, LLC | $9.642 | 2.524 | 0,01% | Aktien |
| Integrated Wealth Concepts LLC | $6.684 | 1.750 | 0,00% | Aktien |
| Arax Advisory Partners | $6.383 | 1.671 | 0,00% | Aktien |
| Russell Investments Group, Ltd. | $6.085 | 1.593 | 0,00% | Aktien |
| ROYAL BANK OF CANADA | $6.000 | 1.577 | 0,00% | Aktien |
Unternehmensinsider 40 Insider · 16 Führungskräfte · 20 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jesse Shefferman | CEO and President | 29. Juni 2026 M | 691.832 | 0 | 1 | $-882.160 |
| Timothy P Noyes | President and CEO | 31. Januar 2019 A | 0 | 0 | 0 | $0 |
| Patrick Fabbio | Chief Financial Officer | 26. Januar 2026 F | 64.115 | 0 | 0 | $0 |
| Blaine Davis | Chief Financial Officer | 15. Juli 2022 F | 20.662 | 0 | 0 | $0 |
| George Arthur Eldridge, | Sr VP, CFO, Treasr, Asst Secy | 18. Januar 2019 A | 29.132 | 0 | 0 | $0 |
| William Conkling | Chief Commercial Officer | 2. Juni 2026 F | 69.992 | 0 | 0 | $0 |
| Jacqueline Zummo | Chief R&D Officer | 8. April 2026 S | 94.827 | 0 | 2 | $-124.989 |
| Hannah Fry | VP, Controller | 26. Januar 2026 F | 42.723 | 0 | 0 | $0 |
| Leonardo Viana Nicacio | Chief Medical Officer | 16. Januar 2026 A | 78.181 | 0 | 0 | $0 |
| Jathin Bandari | Chief Medical Officer | 19. Januar 2024 A | 56.704 | 0 | 0 | $0 |
| Julio Casoy | Chief Medical Officer | 9. Januar 2020 A | 45.500 | 0 | 0 | $0 |
| Steven Keith Burke | SVP and Chief Medical Officer | 15. März 2019 G | 26.332 | 0 | 0 | $0 |
| Bradley J Hartman | VP, People | 18. Januar 2019 A | — | 0 | 0 | $0 |
| Matthew Paul Kowalsky | VP, Legal and Secretary | 18. Januar 2019 A | 29.479 | 0 | 0 | $0 |
| Scott E. Toner | Senior VP of Commercial | 18. Januar 2019 A | 23.357 | 0 | 0 | $0 |
| Gottlieb Daniel Philip | VP Corporate Development | 18. Januar 2019 A | 244 | 0 | 0 | $0 |
| Michael Edward Solomon | Direktor | 15. Juni 2026 A | 26.500 | 0 | 0 | $0 |
| Jane Huang | Direktor | 15. Juni 2026 A | — | 0 | 0 | $0 |
| Barry P Flannelly | Direktor | 15. Juni 2026 A | — | 0 | 0 | $0 |
| Cynthia Smith | Direktor | 15. Juni 2026 A | — | 0 | 0 | $0 |
| Richard S Levy | Direktor | 15. Juni 2026 A | 51.000 | 0 | 0 | $0 |
| Roger Garceau | Direktor | 15. Juni 2026 A | 33.000 | 0 | 0 | $0 |
| Gregory Sargen | Direktor | 15. Juni 2026 A | 31.000 | 0 | 0 | $0 |
| Luke M Beshar | Direktor | 15. Juni 2026 A | 198.000 | 0 | 0 | $0 |
| Scott Braunstein | Direktor | 9. Juni 2020 A | 26.500 | 0 | 0 | $0 |
| John Gordon Freund | Direktor | 8. November 2019 C | 2.175.882 | 0 | 0 | $0 |
| Hubert Birner | Direktor | 8. Juni 2018 A | 1.943.059 | 0 | 0 | $0 |
| Paul J Hastings | Direktor | 8. Juni 2018 A | — | 0 | 0 | $0 |
| Scott A Canute | Direktor | 8. Juni 2018 A | — | 0 | 0 | $0 |
| Garen G Bohlin | Direktor | 8. Juni 2018 A | 53.312 | 0 | 0 | $0 |
| Jonathan S Leff | Direktor | 8. Juni 2018 A | — | 0 | 0 | $0 |
| Brendan O'Leary | Direktor | 9. Juni 2016 A | 1.387.198 | 0 | 0 | $0 |
| Dmitry Kobyzev | Direktor | 2. Juni 2015 A | 1.165.344 | 0 | 0 | $0 |
| Gregory D Phelps | Direktor | 2. Juni 2015 A | — | 0 | 0 | $0 |
| Opaleye, L.P. | 10%-Eigentümer | 9. Januar 2020 A | 2.208.472 | 0 | 0 | $0 |
| Martin Sebastian Olivo | — | 10. Juni 2021 P | 14.344 | 0 | 0 | $0 |
| Randall Marshall | — | 14. September 2020 S | 585.600 | 0 | 0 | $0 |
| Timothy Haines | — | 12. November 2019 C | 2.144.517 | 0 | 0 | $0 |
| Abingworth LLP | — | 12. November 2019 C | 2.144.517 | 0 | 0 | $0 |
| Stuart A Kingsley | — | 8. Juni 2018 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 8 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn | 8. Januar 2021 | — | Erste Einreichung | — | SEC |
| Opaleye Management Inc., Opaleye, L.P., James Silverman ×3 Einreichungen | 25. September 2020 | — | Erste Einreichung | — | SEC |
| Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn ×6 Einreichungen | 17. Januar 2020 | — | Erste Einreichung | — | SEC |
| Abingworth LLP, Abingworth Bioventures VI, LP | 17. Januar 2020 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP 98-040-3543 ×3 Einreichungen | 14. November 2019 | — | Erste Einreichung | Vorstandskampagne | SEC |
| TVM Life Science Ventures VI L.P., TVM Life Science Ventures VI GmbH & Co. KG, TVM Life Science Ventures Management VI L.P., Hubert Birner, Stefan Fischer, Helmut Schuehsler ×2 Einreichungen | 2. August 2017 | — | Erste Einreichung | Passive Anlage | SEC |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Mgmt III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., James E. Flynn | 29. Juni 2017 | — | Erste Einreichung | Passive Anlage | SEC |
| Skyline Venture Partners Qualified Purchaser Fund IV, L.P., Skyline Venture Management IV, LLC, John G. Freund, Yasunori Kaneko | 3. November 2014 | — | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 22 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 0,16% | 55.748 NS | 31. Mai 2026 | N-PORT |
| IWC · iShares Trust | 0,05% | 175.831 SH | 8. August 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,03% | 141.979 SH | 8. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,02% | 91.844 NS | 31. Mai 2026 | N-PORT |
| IWN · iShares Trust | 0,01% | 470.658 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 300.912 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 45.581 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 22.265 NS | 30. April 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1.336.607 SH | 8. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,01% | 179.929 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 2.419 NS | 31. Mai 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 3.715 NS | 30. April 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 1.891 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 1.912 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 48 NS | 31. Mai 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 5.791 NS | 30. April 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 18.477 NS | 30. April 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 7.914 NS | 30. April 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 20.174 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 586.965 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.657.879 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.185 SH | 8. August 2026 | Täglich |